Saturday 17 October 2026
Export MXCT’s income statement to Excel — free account
MaxCyte, Inc.
MXCT Healthcare Medical Devices
MaxCyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $33.0 million, down 14.5% from fiscal 2024. In the quarter to June 2026, revenue fell 14.5%, EPS grew 33.3% and free cash flow grew 54.7%, each against the same quarter a year earlier.
1.30
0.00
0.00%
Follow MXCT
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
2 | 4 | 3 | 3 | 4 | 5 | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
5.00 | 11.29 | 12.51 | 11.76 | 27.24 | 16.27 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
1.32 | 6.85 | 7.48 | 10.35 | 26.53 | 11.78 | (0.57) | — | — | — |
Altman Z″-Score (non-manufacturers) |
3.25 | 6.40 | 7.62 | 11.37 | 17.15 | (1.29) | (7.67) | (8.77) | — | (7.90) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
(61.35) | (55.77) | 526.34 | (85.55) | (961.68) | (222.70) | 0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
(2.89) | (2.89) | (1.64) | 11.46 | (2.31) | (2.39) | (3.52) | — | — | — |
P/B ratio |
0.96 | 2.11 | 2.22 | 2.05 | 3.51 | 12.82 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
0.97 | 2.11 | 2.22 | 2.05 | 3.51 | 12.82 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
2.02 | 7.42 | 8.55 | 6.74 | 19.86 | 15.13 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(1.94) | (10.38) | (16.28) | (20.18) | (63.04) | (45.09) | 0.00 | 0.00 | 0.00 | 0.00 |
EV/FCF |
(1.85) | (9.79) | (13.91) | (0.98) | (2.41) | (36.48) | 0.00 | 0.00 | 0.00 | 0.00 |
Quick Ratio |
7.47 | 10.09 | 9.75 | 15.58 | 16.77 | 3.44 | 2.14 | 2.94 | 3.94 | 2.50 |
Current Ratio |
8.30 | 10.88 | 10.65 | 16.35 | 17.32 | 3.90 | 2.62 | 3.42 | 4.22 | 2.79 |
Net Debt/EBITDA |
2.21 | 2.91 | 3.28 | 8.32 | 15.15 | 2.98 | 1.00 | 1.16 | 2.21 | 2.88 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 9.50% | 16.33% | 20.84% | 0.00% | 31.15% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.15 | 0.36 | 0.41 | 0.26 | 0.98 |
Asset Turnover |
0.15 | 0.15 | 0.15 | 0.16 | 0.20 | 0.64 | 0.71 | 0.91 | 2.35 | 0.47 |
Operating CF/Net income |
0.77 | 0.67 | 0.57 | 0.63 | 0.56 | 0.74 | 0.68 | 1.18 | 0.98 | 0.61 |
Capex/Depreciation |
(0.34) | 0.86 | 1.25 | (9,385.23) | (198.49) | (1.98) | (2.19) | 0.00 | 0.00 | 0.00 |
Interest Coverage |
— | — | — | (215.44) | (17.42) | (13.39) | (18.24) | (27.39) | (29.88) | (8.31) |
| (23.63%) | (18.73%) | (15.60%) | (9.12%) | (12.89%) | (50.47%) | (87.88%) | (53.85%) | (84.92%) | (28.58%) | |
| (20.20%) | (16.17%) | (13.67%) | (8.26%) | (11.36%) | (28.90%) | (42.21%) | (48.21%) | (166.91%) | (14.86%) | |
ROIC |
(47.39%) | (61.81%) | (47.26%) | (64.22%) | (144.75%) | (204.47%) | (434.02%) | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(36.69%) | (23.38%) | (19.36%) | (9.05%) | (7.27%) | (30.94%) | (70.12%) | (50.12%) | (41.05%) | (33.84%) |
Average Days of Receivables |
38.71 | 44.24 | 51.08 | 107.92 | 74.06 | 72.14 | 54.77 | 107.41 | 83.40 | 78.31 |
Research and Development Expense of Revenue |
63.05% | 57.54% | 57.69% | 44.09% | 45.46% | 67.77% | 81.37% | 67.46% | 80.69% | 38.28% |
Selling, General and Administrative Expense of Revenue |
142.43% | 145.89% | 138.16% | 100.50% | 93.46% | 59.99% | 62.01% | 72.00% | 58.79% | 72.67% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
27.90% | 33.87% | 33.86% | 26.55% | 23.48% | 9.45% | 8.10% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
0.53 | 0.32 | 0.30 | 0.42 | 0.27 | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(27.74%) | (9.38%) | (7.40%) | (4.49%) | (2.14%) | (2.77%) | (2.77%) | (2.77%) | (2.77%) | (2.77%) |
Free Cash Flow Yield |
(21.93%) | (6.71%) | (4.91%) | (58.71%) | (30.25%) | (2.55%) | 0.00% | 0.00% | 0.00% | 0.00% |
Revenue per Share |
0.31 | 0.37 | 0.40 | 0.44 | 0.37 | 0.38 | 0.38 | 0.42 | 0.39 | 0.34 |
Operating CF per Share |
(0.32) | (0.26) | (0.21) | (0.15) | (0.12) | (0.13) | (0.16) | (0.26) | (0.27) | (0.06) |
Capex per Share |
(0.02) | (0.02) | (0.04) | (2.86) | (2.96) | (0.03) | (0.02) | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(0.34) | (0.28) | (0.25) | (3.01) | (3.08) | (0.16) | (0.18) | (0.26) | (0.27) | (0.06) |
Cash per Share |
0.97 | 1.47 | 1.63 | 2.24 | 2.81 | 0.50 | 0.30 | 0.36 | 0.70 | 0.35 |
Shareholders Equity per Share |
1.61 | 1.97 | 2.25 | 2.50 | 2.90 | 0.48 | 0.24 | 0.31 | 0.54 | 0.15 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.61 | 1.97 | 2.25 | 2.50 | 2.90 | 0.48 | 0.24 | 0.31 | 0.54 | 0.15 |
Free Cash Flow |
(36.18) | (29.26) | (25.38) | (305.72) | (279.36) | (10.85) | (10.07) | (13.45) | (13.08) | (2.14) |
Working Capital |
104.10 | 155.91 | 172.34 | 236.84 | 254.82 | 33.64 | 15.11 | 20.36 | 31.50 | 10.13 |
Capital Expenditures |
(1.77) | (1.65) | (3.69) | (290.94) | (268.68) | (2.07) | (1.27) | (0.91) | (0.82) | (0.20) |
Net Current Asset Value |
87.35 | 138.47 | 154.09 | 219.58 | 249.21 | 26.70 | 8.07 | 13.42 | 25.34 | 4.80 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.05 | 0.04 | 0.09 | 6.57 | 7.93 | 0.08 | 0.06 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.30 | (0.10) | (0.13) | 0.00 | 0.18 | 0.23 | 0.18 | 0.19 | 0.17 | 0.34 |
Cash ROIC |
(13.18%) | (8.11%) | (6.34%) | (63.52%) | (53.94%) | (14.89%) | (28.61%) | (33.00%) | (19.37%) | (9.80%) |
Accounts Receivable Turnover |
8.07 | 7.39 | 4.38 | 4.43 | 5.63 | 6.22 | 4.54 | 4.03 | 5.62 | 4.01 |
Accounts Payable Turnover |
4.51 | 6.76 | 9.16 | 4.83 | 2.69 | 1.86 | 0.68 | 0.42 | 0.44 | 0.32 |
Inventory Turnover |
0.76 | 0.67 | 0.46 | 0.74 | 0.77 | 0.69 | 0.76 | 1.00 | 1.25 | 0.89 |
Average Days of Payables |
82.19 | 69.81 | 57.19 | 20.91 | 182.16 | 117.43 | 305.15 | 817.94 | 1,087.89 | 967.62 |
Days of Inventory on Hand |
442.73 | 458.25 | 941.29 | 614.37 | 520.83 | 569.31 | 540.64 | 444.90 | 338.35 | 406.81 |
Average Receivables |
4.09 | 5.23 | 9.43 | 9.98 | 6.02 | 4.21 | 4.77 | 5.30 | 3.36 | 2.80 |
Average Payables |
1.38 | 1.05 | 0.52 | 1.06 | 1.36 | 1.49 | 3.69 | 5.57 | 4.51 | 3.75 |
Average Inventory |
8.23 | 10.57 | 10.41 | 6.89 | 4.76 | 4.01 | 3.29 | 2.35 | 1.58 | 1.34 |
Average Assets |
220.99 | 253.87 | 277.46 | 285.39 | 167.95 | 40.88 | 30.55 | 23.59 | 8.03 | 23.71 |
Average Common Equity |
188.87 | 219.21 | 243.07 | 258.43 | 148.06 | 23.41 | 14.67 | 21.11 | 15.78 | 12.33 |
Columns are period end dates